Gilead Remains Committed to Maintaining Advancing Access® Program for HIV Prevention and Treatment Medicines
Foster City, Calif., September 23, 2020 – Gilead has received questions from the HIV community regarding the status of our Advancing Access support plans for individuals currently using Atripla®, Truvada® or Descovy®, following the loss of exclusivity for Atripla and Truvada in the United States.
With a few exceptions due to state laws regarding generic medicines (see below), qualified individuals will currently continue to receive assistance for Atripla, Truvada and Descovy under the Advancing Access patient support offerings and co-pay coupon programs.
Gilead is committed to ensuring that our medications are available to all who need them and believes people should be able to work together with their healthcare provider to determine the most appropriate HIV prevention or treatment strategy for them. At this time, we do not anticipate making changes to any of the Advancing Access support offerings or co-pay coupon programs for our other HIV medications. We remain committed to providing assistance to those living with or at risk of HIV.
Note on exceptions due to existing laws: State-specific laws in California and Massachusetts restrict co-pay assistance in certain circumstances. As a result, on October 31, 2020, co-pay coupon cards will discontinue for Truvada for treatment for people in California, and for Truvada for treatment, Truvada for PrEP® and Atripla for people in Massachusetts.
As of September 30, 2020, no new patients may enroll in the Advancing Access co-pay coupon program for Truvada for treatment in California, and all co-pay coupon cards will be deactivated on October 31, 2020.
As of September 30, 2020, no new patients may enroll in the Advancing Access co-pay coupon program for Truvada for treatment, Truvada for PrEP and Atripla in Massachusetts, and all co-pay coupon cards will be deactivated on October 31, 2020.
For further information, or to clarify any questions about the patient support programs that Gilead offers for eligible patients, please visit GileadAdvancingAccess.com or call 1-800-226-2056.
For information about the approved uses and important safety information for Atripla (efavirenz, emtricitabine, and tenofovir disoproxil fumarate; 600/200/300 mg), Descovy (emtricitabine and tenofovir alafenamide; 200/25 mg), and Truvada (emtricitabine and tenofovir disoproxil fumarate; 200/300 mg), please see the full Prescribing Information including BOXED WARNINGS, available at Gilead.com.
U.S. Prescribing Information for Atripla, Descovy and Truvada, including BOXED WARNINGS, is available at www.gilead.com.
Atripla, Descovy, Truvada, Truvada for PrEP and Gilead are trademarks of Gilead Sciences, Inc. or its related companies.
For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.